Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | FPR1 | P21462 | 2/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488680 | 0.88 | TSHR (0.38) | MEN1KMT2AFPR1FPR2MAPT | |
| SCHEMBL6484092 | 0.78 | MEN1 (0.38) | MEN1KMT2AFPR1GRM4KDM4E | |
| SCHEMBL6484773 | 0.78 | MEN1 (0.41) | MEN1KMT2ATP53FPR1KDM4E | |
| SCHEMBL6486582 | 0.77 | MAPT (0.46) | MEN1KMT2ATP53MAPT | |
| SCHEMBL6919813 | 0.74 | PTGER4 (0.45) | TP53MAPTMMP13 | |
| SCHEMBL6489420 | 0.70 | GRM4 (0.35) | GRM4 | |
| SCHEMBL6478515 | 0.70 | GRM4 (0.33) | TP53GRM4 | |
| SCHEMBL6484094 | 0.68 | LMNA (0.42) | MEN1KMT2AFPR1FPR2MAPT | |
| SCHEMBL6477198 | 0.68 | TSHR (0.38) | MEN1KMT2AFPR1PDE3BPDE3A | |
| SCHEMBL6490898 | 0.67 | TSHR (0.37) | MEN1KMT2AFPR1KDM4EFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897223-B2 | Pyridine fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MEN1 3457/4885KMT2A 2335/4885TP53 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.